Publikationen von 0000-0001-9559-1330
(ORCID: 0000-0001-9559-1330)

Serve, Hubert , Krug, Utz, Wagner, Ruth, Sauerland, M. Cristina, Heinecke, Achim, Brunnberg, Uta, Schaich, Markus, Ottmann, Oliver , Duyster, Justus, Wandt, Hannes, Fischer, Thomas, Giagounidis, Aristoteles, Neubauer, Andreas, Reichle, Albrecht, Aulitzky, Walter, Noppeney, Richard, Blau, Igor, Kunzmann, Volker, Stuhlmann, Reingard, Krämer, Alwin, Kreuzer, Karl-Anton, Brandts, Christian , Steffen, Björn, Thiede, Christian , Müller-Tidow, Carsten, Ehninger, Gerhard und Berdel, Wolfgang E. (2013) Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial. Journal of Clinical Oncology 31 (25), S. 3110-3118. Volltext nicht vorhanden.

Pfeifer, Heike, Goekbuget, Nicola, Völp, Christian, Hüttmann, Andreas, Lübbert, Michael, Stuhlmann, Reingard, Dengler, Julanta, Kreuzer, Karl-Anton, Beck, Joachim, Stelljes, Matthias, Schmid, Mathias, Wassmann, B., Leimer, Lothar, Spiekermann, Karsten, Terwey, Theis H, Schäfer-Eckart, K., Ditz, D., Lindemann, H., Morgner, A., Schaich, Markus, Burmeister, Thomas, Binckebanck, A., Hoelzer, Dieter und Ottmann, Oliver G. (2010) Long-Term Outcome of 335 Adult Patients Receiving Different Schedules of Imatinib and Chemotherapy as Front-Line Treatment for Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Blood 116 (21), S. 173. Volltext nicht vorhanden.

Serve, Hubert, Wagner, Ruth, Sauerland, Cristina, Brunnberg, Uta, Krug, Utz, Schaich, Markus, Ottmann, Oliver G. , Duyster, Justus, Wandt, Hannes, Herr, Wolfgang, Giagounidis, Aristoteles A.N., Neubauer, Andreas, Reichle, Albrecht, Aulitzky, Walter E., Noppeney, Richard, Blau, Igor Wolfgang, Kunzmann, Volker, Schmitz, Norbert, Kreuzer, Karl-Anton, Krämer, Alwin, Brandts, Christian, Steffen, Björn, Heinecke, Achim, Thiede, Christian, Müller-Tidow, Carsten, Ehninger, Gerhard und Berdel, Wolfgang E. (2010) Sorafenib In Combination with Standard Induction and Consolidation Therapy In Elderly AML Patients: Results From a Randomized, Placebo-Controlled Phase II Trial. Blood 116 (21), S. 333. Volltext nicht vorhanden.

Wassmann, B., make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference, make_name_string expected hash reference und make_name_string expected hash reference (2006) Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood 108 (5), S. 1469-1477. Volltext nicht vorhanden.

Müller, M C, Gattermann, N, Lahaye, T, Deininger, M W N, Berndt, A, Fruehauf, S, Neubauer, A, Fischer, T, Hossfeld, D K, Schneller, F, Krause, S W , Nerl, C, Sayer, H G, Ottmann, O G , Waller, C, Aulitzky, W, Coutre, P le, Freund, M, Merx, K, Paschka, P, König, H, Kreil, S, Berger, U, Gschaidmeier, H, Hehlmann, R und Hochhaus, A (2003) Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C. Leukemia 17 (12), S. 2392-2400. Volltext nicht vorhanden.